Skip to main content
OpenTrials
Completed

NCT Number: NCT04851262

Home-based Progressive Resistance Exercise to Enhance Physical Performance of Older Adults With Possible Sarcopenia

The overall aim of the proposed project is to improve muscle strength in older adults with possible sarcopenia by promoting home-based progressive resistance exercise. The target population for health talks is community-dwelling older adults. A Three monthly home-visits and weekly phone calls will be made. A waitlist randomised controlled trial will be conducted to evaluate effectiveness, and qualitative feedback will be collected from participants. A pilot study will be conducted first.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sarcopenia Atrophy Muscular Atrophy Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

65 year–89 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Community

Hong Kong

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

The inclusion criteria are:

  • Aged 65-89;
  • Possible sarcopenia (defined by AWGS 2019);
  • No cognitive impairment (Abbreviated Mental Test score ≥8); and
  • No communication problems.

The exclusion criteria are:

  • having engaged in a structured exercise programme in the past 6 months or planning to do so within the intervention period;
  • mobility-limiting injury of the hands or lower limbs, surgery or hospitalisation within the intervention period;
  • contraindications such as musculoskeletal/cardiorespiratory disorders, or any advanced diseases that inhibit them from exercising.

Treatment and study plan

Exercise

Behavioral

The intervention is to be taught by fitness trainer at the participants' home at the start of each phase. The exercise progression model for older adults recommended by the American College of Sports Medicine, which emphasise gradual increments in training load and systematically alter one or more programme components, will be adopted.

Primary outcomes

  1. Change in lower-limb muscle strength at 12 weeks from baseline

    Time frame: 12 weeks after baseline

    Measured by Short Physical Performance Battery (SPPB), higher score indicates better performance

Secondary outcomes

  1. Change in lower-limb muscle strength at 24 weeks from baseline

    Time frame: 24 weeks after baseline

    Measured by Short Physical Performance Battery (SPPB), higher score indicates better performance

Other outcomes

  1. Change in handgrip strength at 12 weeks from baseline

    Time frame: 12 weeks after baseline

    Measured by a spring-type dynamometer, higher value indicates better performance

  2. Change in handgrip strength at 24 weeks from baseline

    Time frame: 24 weeks after baseline

    Measured by a spring-type dynamometer, higher value indicates better performance

  3. Status of possible sarcopenia at 12 weeks from baseline

    Time frame: 12 weeks after baseline

    Indicated by 5-time chair stand test ≥12 second, or men and women with <28 kg and <18 kg strength

  4. Status of possible sarcopenia at 24 weeks from baseline

    Time frame: 24 weeks after baseline

    Indicated by 5-time chair stand test ≥12 second, or men and women with <28 kg and <18 kg strength

  5. Sarcopenia risk score at 12 weeks from baseline

    Time frame: 12 weeks after baseline

    Measured by SARC-CalF, which is a combination of SARC-F questionnaire and calf circumference, a cut of of >=11 indicates high risk

  6. Sarcopenia risk score at 24weeks from baseline

    Time frame: 24 weeks after baseline

    Measured by SARC-CalF, which is a combination of SARC-F questionnaire and calf circumference, a cut of of >=11 indicates high risk

Sponsors and collaborators

Lead sponsor

The University of Hong Kong

Other

Registry information

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Apr 20, 2021
Registry last updated
Mar 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.